Collectively, these findings indicate that Hsp90 inhibition enhances tumor antigen presentation through multiple mechanisms, including transcriptional induction of differentiation antigens, degradation of client proteins, and proteasome-driven broadening of the antigenic repertoire. The gene discussed is HSP90AB1; the disease is neoplasm.